MedTrace Logo

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

NCT06149247 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-08-20

Study results available
· View outcomes & findings →

Summary

The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.

Conditions

  • Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Interventions

DRUG

Hypericin

HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.

DRUG

Mechlorethamine Topical Gel

Valchlor is an FDA-approved drug for the treatment of CTCL.

Sponsors & Collaborators

  • Soligenix

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-05
Primary Completion
2024-05-31
Completion
2024-06-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06149247 on ClinicalTrials.gov